Products & Tech | Page 24 of 63

Lilly and Boehringer Ingelheim’s New Insulin Glargine Approved in the EU

The European Commission has granted marketing authorisation for Eli Lilly and Company and Boehringer Ingelheim's insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above. The European Commission has granted marketing authorisation for Eli Lilly and Company and Boehringer Ingelheim's insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above.

Lilly’s New Basal Insulin Peglispro (BIL) Proves Better Than Lantus in Phase 3 Trials

Eli Lilly's new basal insulin peglispro (BIL) demonstrated a statistically significant lower hemoglobin A1c (HbA1c) compared with insulin glargine (Lantus) at 26 weeks and 52 weeks, respectively, in the IMAGINE-1 and IMAGINE-3 Phase III clinical trials in patients with type 1 diabetes.

The End of Finger Pricks? Abbott’s New FreeStyle Libre System Approved for Sale in Europe

Abbott has received CE Mark for its its revolutionary CGM system, the FreeStyle Libre Flash Glucose Monitoring System, which uses a new glucose sensing technology. The system eliminates the need for routine finger pricks, reading glucose levels through a sensor that can be worn on the back of the upper arm for up to 14 days. In addition, no finger prick calibration is needed--a key differentiator from current continuous glucose monitoring systems.

FDA Approves First Test For Diagnosing Type 1 Diabetes

The U.S. FDA has allowed marketing of the first zinc transporter 8 autoantibody (ZnT8Ab) test that can help determine if a person has type 1 diabetes and not another type of diabetes. When used with other tests and patient clinical information, the test may help some people with type 1 diabetes receive timely diagnosis and treatment for their disease. Early treatment of type 1 diabetes is important in helping to prevent further deterioration of insulin producing cells.

FDA Grants Tentative Approval to Lilly’s New Insulin Glargine Injection Basaglar

The U.S. FDA has granted tentative approval for Basaglar (insulin glargine injection). With a tentative approval, the FDA has determined that…

Sanofi Licenses Afrezza Inhaled Insulin from MannKind

Sanofi and MannKind Corporation have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin

Summer and Diabetes: Four Gadgets That Will Make Your Life More Delicious

Summer with diabetes can be tough. It’s the season of beer and sangria, juicy watermelon, sweet corn, and, at least if you’re in my neighborhood, a full hour of the Mr. Softee truck’s siren song every single afternoon. So this summer, I decided to search for diabetes-friendly kitchen gadgets that would enable me to enjoy summer and keep my diabetes under control.

A Novel Approach to Treating Type 2 Diabetes: Short-Term Intensive Insulin Therapy

Dr. Mariela Glandt, an endocrinologist and director of the Diabetes Medical Center in Tel Aviv uses a short course of intensive insulin therapy in order to "reset" beta cells and help them return to an earlier and more manageable stage of the disease.

Inhaled Insulin for Diabetes: Is Afrezza Worth the Risks?

Will I prescribe Afrezza for people with diabetes? Not a lot, and not for past or present smokers, and not for people with any breathing problems (or heart issues that might cause difficulty breathing), and not without getting pulmonary function testing and explaining all of what I see as potential risks, and not without close follow-up.

The Insulin Games: A Race to Dominate the Growing Market

New long-acting insulin configurations are being developed and launched because the patent on Lantus is set to expire soon. In the United States the Lantus patent expires February 2015 and the drug’s patent expires in Europe in May 2015.